Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 12/2018

01-12-2018 | Original Article

Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies

Authors: Hongye Wang, Ting Yuan, Tingting Li, Yanpeng Li, Feng Qian, Chuanwu Zhu, Shujia Liang, Daniel Hoffmann, Ulf Dittmer, Binlian Sun, Rongge Yang

Published in: Archives of Virology | Issue 12/2018

Login to get access

Abstract

Broadly neutralizing antibodies (bNAbs) are very promising agents for HIV-1 prophylaxis and AIDS treatment. However, the neutralization susceptibility of circulating recombinants such as CRF01_AE, which is becoming increasingly prevalent, has not been studied in detail until now. Here, we focused on CRF01_AE in China and aimed to find bNAbs that can be used for neutralization of CRF01_AE. Full-length env clones were obtained from the plasma samples of 22 HIV-1-infected individuals sampled in 2009 and 2015. An env-pseudovirus-based neutralization assay was conducted using five categories of bNAbs: VRC01, NIH45-46G54W, and 3BNC117 (targeting the CD4 binding site); PG9 and PG16 (targeting the V1V2 loop); 2G12 (glycan specific), PGT121 and 10-1074 (targeting the V3 glycan); 2F5, 4E10, and 10E8 (targeting the membrane-proximal external region (MPER)). The neutralizing efficiency was compared, and features of the escape pseudoviruses were analyzed. The CRF01_AE pseudoviruses exhibited different susceptibility to these bNAbs. Overall, 4E10, 10E8, and 3BNC117 neutralized all 22 env-pseudotyped viruses, followed by NIH45-46G54W and VRC01, which neutralized more than 90% of the viruses. 2F5, PG9, and PG16 showed only moderate breadth, while the other three bNAbs neutralized none of these pseudoviruses. Specifically, 10E8, NIH45-46G54Wand 3BNC117 showed the highest efficiency, combining neutralization potency and breadth. Mutations at position 160, 169, 171 were associated with resistance to PG9 and PG16, while loss of a potential glycan at position 332 conferred insensitivity to V3-glycan-targeting bNAbs. Our results may help for choosing bNAbs that can be used preferentially for prophylactic or therapeutic approaches in China.
Appendix
Available only for authorised users
Literature
1.
Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME et al (2016) Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. N Engl J Med 375:2037–2050PubMedPubMedCentralCrossRef
2.
Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J et al (2013) Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503:224–228PubMedPubMedCentralCrossRef
3.
Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C et al (2004) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78:13232–13252PubMedPubMedCentralCrossRef
4.
Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV (2016) Bispecific anti-HIV-1 antibodies with enhanced breadth and potency. Cell 165:1609–1620PubMedPubMedCentralCrossRef
5.
Bouvin-Pley M, Morgand M, Moreau A, Jestin P, Simonnet C, Tran L et al (2013) Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic. PLoS Pathog 9:e1003477PubMedPubMedCentralCrossRef
6.
Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N et al (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70:1100–1108PubMedPubMedCentral
7.
Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Purtscher M et al (1994) Generation of human monoclonal-antibodies against Hiv-1 proteins—electrofusion and epstein-barr-virus transformation for peripheral-blood lymphocyte immortalization. AIDS Res Hum Retrovir 10:359–369PubMedCrossRef
8.
Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP Jr, Buckley N et al (2015) Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522:487–491PubMedPubMedCentralCrossRef
9.
Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF et al (2017) Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat Med 23:185–191PubMedPubMedCentralCrossRef
10.
Chen D, He X, Ye J, Zhao P, Zeng Y, Feng X (2016) Genetic and phenotypic analysis of CRF01_AE HIV-1 env clones from patients residing in Beijing, China. AIDS Res Hum Retrovir 32:1113–1124PubMedCrossRef
11.
Cheng HH, Zhang JP, Capizzi J, Young NL, Mastro TD (1994) Hiv-1 subtype-E in Yunnan, China. Lancet 344:953–954PubMedCrossRef
12.
Chong H, Hong K, Zhang C, Nie J, Song A, Kong W, Wang Y (2008) Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China. J Acquir Immune Defic Syndr 47:535–543PubMedCrossRef
13.
Chun TW, Murray D, Justement JS, Blazkova J, Hallahan CW, Fankuchen O et al (2014) Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. Proc Natl Acad Sci USA 111:13151–13156PubMedCrossRefPubMedCentral
14.
Diskin R, Scheid JF, Marcovecchio PM, West AP Jr, Klein F et al (2011) Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334:1289–1293PubMedPubMedCentralCrossRef
15.
Doria-Rose NA, Georgiev I, O’Dell S, Chuang GY, Staupe RP, McLellan JS et al (2012) A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J Virol 86:8319–8323PubMedPubMedCentralCrossRef
16.
Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS et al (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491:406–412PubMedPubMedCentralCrossRef
17.
Huang X (1992) A contig assembly program based on sensitive detection of fragment overlaps. Genomics 14:18–25PubMedCrossRef
18.
Huang Y, Yu J, Lanzi A, Yao X, Andrews CD, Tsai L et al (2016) Engineered bispecific antibodies with exquisite HIV-1-neutralizing activity. Cell 165:1621–1631PubMedPubMedCentralCrossRef
19.
Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S et al (2012) HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492:118–124PubMedCrossRef
20.
21.
Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME et al (2015) Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol 182:289–301PubMedPubMedCentralCrossRef
22.
Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G et al (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79:10108–10125PubMedPubMedCentralCrossRef
23.
Li X, Li W, Zhong P, Fang K, Zhu K, Musa TH et al (2016) Nationwide trends in molecular epidemiology of HIV-1 in China. AIDS Res Hum Retrov 32:851–859CrossRef
24.
Li Y, Han Y, Xie J, Gu L, Li W, Wang H et al (2014) CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission. Aids 28:521–530PubMedCrossRef
25.
Lu CL, Murakowski DK, Bournazos S, Schoofs T, Sarkar D, Halper-Stromberg A et al (2016) Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352:1001–1004PubMedPubMedCentralCrossRef
26.
27.
28.
Nie J, Zhang C, Liu W, Wu X, Li F, Wang S, Liang F, Song A, Wang Y (2010) Genotypic and Phenotypic Characterization of HIV-1 CRF01_AE env Molecular Clones From Infections in China. JAIDS J Acquir Immune Defic Syndr 53:440–450PubMedCrossRef
29.
30.
Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK et al (2011) A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334:1097–1103PubMedPubMedCentralCrossRef
31.
Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY et al (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633–1637PubMedPubMedCentralCrossRef
32.
Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu CL, Lorenzi JC et al (2016) HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535:556PubMedPubMedCentralCrossRef
33.
Schoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A, Nogueira L et al (2016) HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352:997–1001PubMedPubMedCentralCrossRef
34.
Shang H, Han X, Shi X, Zuo T, Goldin M, Chen D et al (2011) Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in China. J Biol Chem 286:14531–14541PubMedPubMedCentralCrossRef
35.
Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R et al (2013) Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503:277–280PubMedPubMedCentralCrossRef
36.
37.
Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, Katinger H (2001) A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retrovir 17:1757–1765PubMedCrossRef
38.
Sun M, Li Y, Zheng H, Shao Y (2016) Recent progress toward engineering HIV-1-specific neutralizing monoclonal antibodies. Front Immunol 7:391PubMedPubMedCentral
39.
Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL et al (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285–289PubMedPubMedCentralCrossRef
40.
Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS et al (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856–861PubMedPubMedCentralCrossRef
41.
Xu L, Pegu A, Rao E, Doria-Rose N, Beninga J, McKee K et al (2017) Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science 358:85–90PubMedPubMedCentralCrossRef
42.
Yuan R, Cheng H, Chen LS, Zhang X, Wang B (2016) Prevalence of different HIV-1 subtypes in sexual transmission in China: a systematic review and meta-analysis. Epidemiol Infect 144:2144–2153PubMedCrossRef
Metadata
Title
Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies
Authors
Hongye Wang
Ting Yuan
Tingting Li
Yanpeng Li
Feng Qian
Chuanwu Zhu
Shujia Liang
Daniel Hoffmann
Ulf Dittmer
Binlian Sun
Rongge Yang
Publication date
01-12-2018
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 12/2018
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-018-4011-7

Other articles of this Issue 12/2018

Archives of Virology 12/2018 Go to the issue

Brief Report

Diversity of three bunya-like viruses infecting apple

Brief Report

A metagenomic study of the rumen virome in domestic caprids

Original Article

Laboratory detection and molecular phylogenetic analysis of severe fever with thrombocytopenia syndrome virus in Hubei Province, central China

Brief Report

Host range and molecular characterization of a lytic Pradovirus-like Ralstonia phage RsoP1IDN isolated from Indonesia

Correction

Correction to: IL-1b is a key cytokine that induces trypsin upregulation in the influenza virus–cytokine–trypsin cycle

Correction

Correction to: The expression of HCV-associated host factors is dependent on the hepatoma cell line used in HCV studies
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits